Tamsulosin: Difference between revisions

(Add SMW Indications by Condition query table)
(Switch SMW query from broadtable to table format for better layout with TOC)
 
Line 52: Line 52:
  |?Has Route=Route
  |?Has Route=Route
  |?Has Population=Population
  |?Has Population=Population
  |format=broadtable
  |format=table
  |headers=plain
  |headers=plain
  |mainlabel=-
  |mainlabel=-

Latest revision as of 21:56, 20 March 2026

Administration

  • Type: α-blocker
  • Dosage Forms:
  • Routes of Administration: oral
  • Common Trade Names: Flomax

Adult Dosing

  • 0.4mg PO once daily or nightly

Urolithiasis

  • 0.4mg PO QHS until stone expulsion

Pediatric Dosing

Safety/efficacy not established

Special Populations

Renal Dosing

  • Adult: No adjustment for CrCl >10

Hepatic Dosing

  • Adult: No adjustment

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

  • Headache, dizziness, insomnia, somnolence
  • Abnormal ejaculation
  • Rhinitis
  • Back pain

Pharmacology

  • Half-life: 9-15h
  • Metabolism: CYP3A4 and CYP2D6
  • Excretion: Mostly renal

Mechanism of Action

  • α-1A antagonist→ smooth muscle relaxation in bladder neck, prostate, urethra→ increased urine flow rate

Comments

Indications by Condition

The following table is automatically generated from disease/condition pages across WikEM.

IndicationDoseContextRoutePopulation
Acute urinary retention0.4mg QHSAlpha-blocker for BPH-related retention (outpatient)POAdult
Urolithiasis0.4mg QHSMedical expulsive therapy for stones 5-10mmPOAdult


See Also

References